Claims
- 1. A compound of the chemical formula (I) and its pharmaceutically acceptable salt: ##STR13## wherein Y is C.sub.3 alkylene;
- Z is a valence bond or C.sub.1 -C.sub.6 alkylene;
- R.sup.1 is phenyl, biphenyl, indanyl, naphthyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, tetrazolyl, quinolyl, phenyl C.sub.1 -C.sub.6 alkyl- or benzhydryl, wherein each of the ring moieties may optionally be substituted by one or more substituents independently selected from halogen, C.sub.1 -C.sub.6 alkyl, halosubstituted C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy and halosubstituted C.sub.1 -C.sub.6 alkoxy;
- R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.3 is hydrogen, hydroxy, cyano, amino or carboxy; and
- R.sup.4 represents a group of the formula (II) or (III) ##STR14## wherein X.sup.1, X.sup.2 and X.sup.3 are each halo, hydrogen, nitro, C.sub.1 -C.sub.6 alkyl, halosubstituted C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halosubstituted C.sub.1 -C.sub.6 alkoxy, hydroxy, amino, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl or C.sub.1 -C.sub.6 alkylsulfonyl;
- Q.sup.1 and Q.sup.2 are each H.sub.2, oxygen or sulfur;
- A is valence bond, methylene, oxygen, sulfur or NH;
- R.sup.5 and R.sup.6 are each hydrogen or C.sub.1 -C.sub.6 alkyl; and
- R.sup.7 is hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, halosubstituted C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy;
- provided that when Z is a valence bond, R.sub.3 must be hydrogen.
- 2. A compound according to claim 1, wherein R.sup.4 is the formula (II).
- 3. A compound according to claim 2, wherein Y is propylene.
- 4. A compound according to claim 3, wherein --ZR.sup.3 is hydrogen.
- 5. A compound according to claim 4, wherein R.sup.1 is phenyl.
- 6. A compound according to claim 5, wherein R.sup.2 is attached to the carbon atom adjacent to the nitrogen of NZR.sup.3.
- 7. A compound according to claim 6 selected from ##STR15## wherein in the compound (Ia) the stereochemistry is (2S*,3S*,4R*,5R*) or (2S*,3S*,4S*) and in the compound (Ib) the stereochemistry is (2S*,3S*,5S*).
- 8. A compound according to claim 7, wherein X.sup.1 is 2-methoxy.
- 9. A compound according to claim 8, wherein X.sup.2 is hydrogen and X.sup.3 is (C.sub.1 -C.sub.6) alkyl or trifluoro (C.sub.1 -C.sub.6) alkoxy.
- 10. A compound selected from the following:
- (2S*,3S*,4S*,5R*)-4-Carboxy-3-[N-(5-Isopropyl-2-methoxy-benzyl)amino]-5-methyl-2-phenylpyrrolidine and (2S*,3S*,5S*)-5-Carboxy-3-[N-(2-methoxy-5-trifluoromethoxybenzyl)amino]-2-phenylpiperidine.
- 11. A pharmaceutical composition for the treatment of gastrointestinal pain, migraine or emesis in a mammalian subject, which comprises a therapeutically effective amount of a compound of claim 1 or its pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier.
- 12. A method of treating gastrointestinal disorders, central nervous system disorders, allergy, inflammatory diseases, asthma, pain, migraine or emesis in a mammalian subject, which comprises administering to the said subject a therapeutically effective amount of a compound of claim 1 or its pharmaceutically acceptable salt.
Priority Claims (1)
Number |
Date |
Country |
Kind |
5-255064 |
Sep 1993 |
JPX |
|
Parent Case Info
This is a continuation of U.S. Ser. No. 08/957,176, filed Oct. 24, 1997, abandoned, which was a continuation of U.S. Ser. No. 617,896, filed Mar. 13, 1996, abandoned, which was filed under 35 USC 371 from PCT/JP94/01514, filed on Sep. 13, 1994.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5232929 |
Desai et al. |
Aug 1993 |
|
Foreign Referenced Citations (7)
Number |
Date |
Country |
0610021 |
Aug 1994 |
EPX |
WO9109844 |
Jul 1991 |
WOX |
WO9210476 |
Jun 1992 |
WOX |
WO9220676 |
Nov 1992 |
WOX |
WO9300331 |
Jan 1993 |
WOX |
WO9319064 |
Sep 1993 |
WOX |
WO9410170 |
May 1994 |
WOX |
Continuations (2)
|
Number |
Date |
Country |
Parent |
957176 |
Oct 1997 |
|
Parent |
617896 |
|
|